The Utility of Galactomannan and Polymerase Chain Reaction Assays in Bronchoalveolar Lavage for Diagnosis of Chronic Pulmonary Aspergillosis.

IF 3.6 3区 生物学 Q2 MYCOLOGY
Mycopathologia Pub Date : 2023-12-01 Epub Date: 2023-10-20 DOI:10.1007/s11046-023-00797-z
Mohit Chowdhury, Gagandeep Singh, Mragnayani Pandey, Himanshu Mishra, Ved Prakash Meena, Prayas Sethi, Amandeep Singh, Bindu Prakash, Ashish Datt Upadhyay, Anant Mohan, Sanjeev Sinha, Immaculata Xess, Naveet Wig, Sushil Kumar Kabra, Animesh Ray
{"title":"The Utility of Galactomannan and Polymerase Chain Reaction Assays in Bronchoalveolar Lavage for Diagnosis of Chronic Pulmonary Aspergillosis.","authors":"Mohit Chowdhury, Gagandeep Singh, Mragnayani Pandey, Himanshu Mishra, Ved Prakash Meena, Prayas Sethi, Amandeep Singh, Bindu Prakash, Ashish Datt Upadhyay, Anant Mohan, Sanjeev Sinha, Immaculata Xess, Naveet Wig, Sushil Kumar Kabra, Animesh Ray","doi":"10.1007/s11046-023-00797-z","DOIUrl":null,"url":null,"abstract":"<p><p>The diagnosis of chronic pulmonary aspergillosis (CPA) is established by combined clinic-radio-microbiological criteria. Out of the different microbiological criteria, a positive serology for Aspergillus-specific IgG levels is the cornerstone of diagnosis. Alternatively, other microbiological evidence are sometimes sought viz., positive Aspergillus antigen (broncho-alveolar lavage fluid, i.e., BALF galactomannan ≥ 1.0), histopathological demonstration of the fungi following lung biopsy or resection, demonstration of hyaline septate hyphae in direct microscopy resembling Aspergillus spp. or its growth on a respiratory specimen. However, the exact roles of BALF- GM and the newer BALF-PCR have not been confirmed by studies till date. This study enrolled 210 patients with suspected CPA. Of the participants, 88 patients met the criteria for CPA, whereas 122 patients had an alternative diagnosis. The sensitivity-specificity of AsperGenius® PCR and \"in-house\" PCR were 52.27(36.69-67.54) %-33.78 (23.19-45.72) % and 36.36 (22.41-52.23) %-39.19 (28.04-51.23) % respectively. The sensitivity/specificity of BALF (> 1.0) and serum galactomannan (> 1.0) were 46.55% (33.34-60.13)/64.08% (54.03-73.3) and 29.82% (22.05-37.6)/86.84% (81.1-92.59) respectively. The optimal cut-off values for BALF-Galactomannan and serum galactomannan in diagnosing CPA were found to be 0.69 (sensitivity: 64%; specificity: 53%) and 0.458 (sensitivity: 67%; specificity: 64%) respectively. This results of this study suggests that Aspergillus PCR from BAL may not be a good \"rule-in\" test for diagnosing CPA. While the performances of GM in BAL and serum may be better than PCR, it should be best used in conjunction with other clinical, radiological, and other microbiological characteristics.</p>","PeriodicalId":19017,"journal":{"name":"Mycopathologia","volume":null,"pages":null},"PeriodicalIF":3.6000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mycopathologia","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1007/s11046-023-00797-z","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/10/20 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MYCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The diagnosis of chronic pulmonary aspergillosis (CPA) is established by combined clinic-radio-microbiological criteria. Out of the different microbiological criteria, a positive serology for Aspergillus-specific IgG levels is the cornerstone of diagnosis. Alternatively, other microbiological evidence are sometimes sought viz., positive Aspergillus antigen (broncho-alveolar lavage fluid, i.e., BALF galactomannan ≥ 1.0), histopathological demonstration of the fungi following lung biopsy or resection, demonstration of hyaline septate hyphae in direct microscopy resembling Aspergillus spp. or its growth on a respiratory specimen. However, the exact roles of BALF- GM and the newer BALF-PCR have not been confirmed by studies till date. This study enrolled 210 patients with suspected CPA. Of the participants, 88 patients met the criteria for CPA, whereas 122 patients had an alternative diagnosis. The sensitivity-specificity of AsperGenius® PCR and "in-house" PCR were 52.27(36.69-67.54) %-33.78 (23.19-45.72) % and 36.36 (22.41-52.23) %-39.19 (28.04-51.23) % respectively. The sensitivity/specificity of BALF (> 1.0) and serum galactomannan (> 1.0) were 46.55% (33.34-60.13)/64.08% (54.03-73.3) and 29.82% (22.05-37.6)/86.84% (81.1-92.59) respectively. The optimal cut-off values for BALF-Galactomannan and serum galactomannan in diagnosing CPA were found to be 0.69 (sensitivity: 64%; specificity: 53%) and 0.458 (sensitivity: 67%; specificity: 64%) respectively. This results of this study suggests that Aspergillus PCR from BAL may not be a good "rule-in" test for diagnosing CPA. While the performances of GM in BAL and serum may be better than PCR, it should be best used in conjunction with other clinical, radiological, and other microbiological characteristics.

Abstract Image

半乳甘露聚糖和聚合酶链反应在支气管肺泡灌洗中诊断慢性肺曲霉菌病的应用。
慢性肺曲霉菌病(CPA)的诊断是通过联合临床放射性微生物学标准建立的。在不同的微生物学标准中,曲霉特异性IgG水平的阳性血清学是诊断的基石。或者,有时也会寻求其他微生物学证据,即阳性曲霉菌抗原(支气管肺泡灌洗液,即BALF半乳甘露聚糖 ≥ 1.0),肺活检或切除后真菌的组织病理学证明,直接显微镜下类似曲霉属的透明隔菌丝的证明,或其在呼吸标本上的生长。然而,迄今为止,BALF-GM和新的BALF-PCR的确切作用尚未得到研究的证实。本研究纳入了210名疑似CPA患者。在参与者中,88名患者符合CPA标准,而122名患者有替代诊断。AsperGenius®PCR和“内部”PCR的敏感性特异性分别为52.27(36.69-67.54)%-33.78(23.19-45.72)%和36.36(22.41-52.23)%-39.19(28.04-51.23)%。BALF的敏感性/特异性(> 1.0)和血清半乳甘露聚糖(> 1.0)分别为46.55%(33.34-60.13)/64.08%(54.03-73.3)和29.82%(22.05-37.6)/86.84%(81.1-92.59)。BALF半乳甘露聚糖和血清半乳甘露聚糖诊断CPA的最佳临界值分别为0.69(敏感性:64%;特异性:53%)和0.458(敏感性:67%;特异性;64%)。这项研究的结果表明,来自BAL的曲霉菌PCR可能不是诊断CPA的良好“规则”测试。虽然GM在BAL和血清中的表现可能比PCR更好,但它最好与其他临床、放射学和其他微生物学特征结合使用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Mycopathologia
Mycopathologia 生物-真菌学
CiteScore
6.80
自引率
3.60%
发文量
76
审稿时长
3 months
期刊介绍: Mycopathologia is an official journal of the International Union of Microbiological Societies (IUMS). Mycopathologia was founded in 1938 with the mission to ‘diffuse the understanding of fungal diseases in man and animals among mycologists’. Many of the milestones discoveries in the field of medical mycology have been communicated through the pages of this journal. Mycopathologia covers a diverse, interdisciplinary range of topics that is unique in breadth and depth. The journal publishes peer-reviewed, original articles highlighting important developments concerning medically important fungi and fungal diseases. The journal highlights important developments in fungal systematics and taxonomy, laboratory diagnosis of fungal infections, antifungal drugs, clinical presentation and treatment, and epidemiology of fungal diseases globally. Timely opinion articles, mini-reviews, and other communications are usually invited at the discretion of the editorial board. Unique case reports highlighting unprecedented progress in the diagnosis and treatment of fungal infections, are published in every issue of the journal. MycopathologiaIMAGE is another regular feature for a brief clinical report of potential interest to a mixed audience of physicians and laboratory scientists. MycopathologiaGENOME is designed for the rapid publication of new genomes of human and animal pathogenic fungi using a checklist-based, standardized format.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信